Mareev Yu V, Gilarevsky S R, Begrambekova Yu L, Lopatin Yu M, Garganeeva A A, Duplyakov D V, Kobalava Zh D, Golukhova E Z, Koziolova N A, Panov А V, Lelyavina Т А, Drapkina O M, Mareev V Yu
National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia Robertson Centre for Biostatistics, Glasgow, Great Britain.
Russian Medical Academy of Postgraduate Education, Moscow, Russia.
Kardiologiia. 2021 May 3;61(4):73-78. doi: 10.18087/cardio.2021.4.n1639.
In recent years there has been significant interest in treating iron deficiency (ID) in patients with heart failure (HF) due to its high prevalence and detrimental effects in this population. As stated in the 2020 Russain HF guidelines, Intravenous ferric carboxymaltose remains the only proven therapy for ID.This document was prompted by the results from the recent AFFIRM-AHF trial which demonstrates that treatment of ID after acute HF decompensation reduces the risk of future decompensations. Experts have concluded that in HF patients with acute decompensation, a left ventricular ejection fraction of < 50% and ID, Intravenous ferric carboxymaltose reduces future HF hospitalisations. Patients with stable HF may also benefit from treatment of ID to improve quality of life and alleviate symptoms. It is, therefore, reasonable to screen for and treat ID in patients with HF.
近年来，由于缺铁（ID）在心力衰竭（HF）患者中的高患病率及其对该人群的有害影响，人们对治疗心力衰竭患者的缺铁问题产生了浓厚兴趣。正如2020年俄罗斯心力衰竭指南所述，静脉注射羧麦芽糖铁仍然是治疗缺铁的唯一经证实的疗法。这份文件是受最近的AFFIRM-AHF试验结果的推动而产生的，该试验表明，急性心力衰竭失代偿后治疗缺铁可降低未来失代偿的风险。专家们得出结论，对于急性失代偿、左心室射血分数<50%且缺铁的心力衰竭患者，静脉注射羧麦芽糖铁可减少未来心力衰竭住院次数。稳定心力衰竭患者也可能从缺铁治疗中受益，以改善生活质量和缓解症状。因此，对心力衰竭患者进行缺铁筛查和治疗是合理的。
Zotero 插件